GH-releasing peptide
GHRP-6
GHRP-6 after one dose: 50% at ~20 min, 25% at 40 min, 12.5% at 60 min.
Drawn from the half-life in the app's model, ~20 min. The model's figures
- Compound
- GHRP-6
- Symbol
- GR6
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 24
- Checked
- Last reviewed . Sources are listed below.
Overview
GHRP-6 (growth hormone-releasing peptide-6) is a hexapeptide with the sequence His-DTrp-Ala-Trp-DPhe-Lys-NH2 and a molecular weight of 872.44 daltons.1,2 Bowers and colleagues at Tulane University reported in the Journal of Clinical Endocrinology and Metabolism in 1990 that GHRP-6 given as an intravenous bolus to 18 normal men raised serum growth hormone (GH) at each of three doses.1 A 1995 paper describes GHRP-6 as having GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man, without giving subcutaneous data in its summary.4 In a 2000 Lancet study, GHRP-6 given with GH-releasing hormone (GHRH) was used as a diagnostic test for adult GH deficiency in 125 adults with organic pituitary disease and 125 healthy people.5 GHRP-6 is named in section S2.2.4 of the WADA 2026 Prohibited List and appears under 503B on FDA's category 2 list of bulk drug substances that may present significant safety risks.3,6
The app lists a half-life of about 20 minutes, 95% bioavailability, a typical dose of 100 to 300 mcg a day, a time to peak of about 15 minutes and subcutaneous injection as the route. The figures row and the evidence grade are the app's, not figures taken from a study.
How it works
Receptor and growth hormone release
A 2026 review by Dominikowski and colleagues in Frontiers in Endocrinology describes GHRP-6 as a ghrelin receptor (GHSR-1a) agonist that robustly stimulates pulsatile GH secretion in controlled human studies.7 In 6 normal subjects given ghrelin, GHRH or GHRP-6 at 1 microgram/kg intravenously, Micic and colleagues reported that ghrelin appeared to be a more potent stimulus than GHRP-6 and GHRH.8
Interaction with GH-releasing hormone and the hypothalamus
Bowers and colleagues found that submaximal GHRP doses of 0.1 and 0.3 microgram/kg given with 1 microgram/kg of GHRH stimulated GH release synergistically, and suggested that GHRP and GHRH act independently.1 In obese subjects, GHRP-6 alone gave a mean GH peak of 15.7 micrograms/L against 6.8 for GHRH alone, and in a separate group the two together gave a mean peak of 42.2 micrograms/L, with individual responses of 14 to 86 micrograms/L.9 In 12 patients with hypothalamopituitary disconnection, GH release after GHRP-6 at 90 micrograms intravenously was blocked (area under the curve 97.3 against 1434.8 micrograms per L over 120 min in 11 matched controls) while the response to GHRH at 100 micrograms intravenously was similar to controls (423.4 against 483.7), and the authors concluded that the main action of GHRP-6 is exerted at the hypothalamic level.10 In 7 children with neonatal pituitary stalk transection, the GH area under the curve after GHRP-6 at 1 microgram/kg intravenously was 37 against 1221 micrograms per L over 90 min in 7 matched controls.11
Findings in animals
In rats, intracerebroventricular injection of GHRP-6 or ghrelin significantly stimulated food intake, and GHRP-6 significantly activated orexin-containing neurons in the lateral hypothalamus (Lawrence and colleagues, Endocrinology, 2002).12 In otherwise healthy rats given doxorubicin, GHRP-6 given in parallel prevented ventricular dilation and preserved left ventricular systolic function (Berlanga-Acosta and colleagues, Frontiers in Pharmacology, 2024).13 Both results are from rats and are not human results.12,13
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~20 min
- Bioavailability
- 95%
- Typical dose
- 100–300 mcg/day
- Route
- SubQ
- Time to peak
- ~15 min
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~20 min | The app's figure. Bowers and colleagues, 1992, reported a serum half-life of 20 min for immunoreactive GHRP after oral doses in 5 normal men, with intravenous data from normal men (number not stated in the summary). Cabrales and colleagues, 2013, reported by LC-MS, averaging all three dose levels, a distribution half-life of 7.6 ± 1.9 min and an elimination half-life of 2.5 ± 1.1 h after intravenous doses in 9 men.14,2 |
| Bioavailability | ~95% | The app's figure. None of the studies cited here reports a subcutaneous bioavailability. Oral GHRP-6 had about 0.3% of the activity of intravenous GHRP-6 in men, calculated by the authors from GH response and not from drug levels, and in dogs, intranasal bioavailability was estimated from GH response data at 34.4 to 44.9%.14,15 |
| Time to peak | ~15 min | The app's figure. After 300 micrograms/kg orally in 5 normal men, the GH rise was detectable at 30 min and peaked between 60 and 75 min, and serum immunoreactive GHRP peaked at 60 min. In conscious dogs, GH peaked 15 min after intranasal dosing.14,15 |
| Route | SubQ | Studies in people gave GHRP-6 intravenously, orally, intranasally and sublingually; Bellone and colleagues, 1995, describe subcutaneous activity in man without data in the summary; and one retrospective cohort reports subcutaneous injection of GHRP-6 together with GHRP-2 and sermorelin.16,17,4,18 |
| Typical dose | 100 to 300 mcg/day | The app's figure. Studies gave, for example, single intravenous doses of 0.1 to 1.0 microgram/kg or oral doses of 100 or 300 micrograms/kg, and the retrospective cohort used 100 mcg of each of three peptides three times daily.1,14,18 |
| Markers to monitor | IGF-1, blood glucose, insulin | The app's list; no cited source recommends monitoring any of these markers. IGF-I was measured in an infusion study, an oral treatment study and a combination-regimen cohort, and FDA names cortisol and blood glucose among its safety concerns.16,19,18,6 |
The chart below illustrates the app's half-life of about 20 minutes and time to peak of about 15 minutes; it is not a study result. The 2013 study reported an elimination half-life of 2.5 hours, and the twice-daily regimen was oral while the three-times-daily regimen combined three peptides.
Animal pharmacokinetics
In rats, orally given GHRP-6 was 0.7% as bioactive as the parenterally given peptide, and in dogs oral potency was 0.8% of parenteral potency (Walker and colleagues, Life Sciences, 1990).20
Deeper analysis: the 2013 intravenous pharmacokinetic study
Cabrales and colleagues, European Journal of Pharmaceutical Sciences, 2013, gave a single intravenous bolus of 100, 200 and 400 micrograms/kg of body weight to nine male healthy volunteers and measured GHRP-6 by liquid chromatography and mass spectrometry.2 Disposition fitted a bi-exponential function, with an Akaike index lower than that of the one-compartment model for all subjects.2 The authors reported a trend for the area under the curve to increase proportionally with dose, and atypical concentration spikes during the elimination phase in four of the nine subjects.2 The authors are at the Center for Genetic Engineering and Biotechnology in Havana, Cuba, and the paper is indexed as a phase I clinical trial.2 PubMed lists no grant and no sponsor for the paper, and the authors' published summary states no limitations.2
Deeper analysis: oral and intravenous dosing in men and children
Bowers, Alster and Frentz gave GHRP-6 orally at 100 and 300 micrograms/kg to 5 normal men and reported that at 300 micrograms/kg the GH rise was detectable at 30 minutes, peaked between 60 and 75 minutes and returned to baseline between 150 and 180 minutes.14 Peak GH rose 63-fold and 202-fold above baseline at 100 and 300 micrograms/kg, and the authors calculated from GH response that oral GHRP has about 0.3% of the activity of intravenous GHRP.14
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Bowers and colleagues, 19901 | Controlled; placebo and GHRH comparators; NIH grants listed in PubMed | 18 normal men | Intravenous bolus 0.1, 0.3 or 1.0 microgram/kg; single dose | Mean peak GH 1.2 (placebo), 7.6, 16.5 and 68.7 micrograms/L; prolactin and cortisol about 2-fold above basal only at 1 microgram/kg; no adverse clinical effects reported for GHRP. |
| Bowers, Alster and Frentz, 199214 | Oral dose study with intravenous comparison | 5 normal men; 9 children with short stature and varying GH deficiency | Oral 100 or 300 micrograms/kg; intravenous 0.1, 0.3, 1.0 microgram/kg in men; single dose | At 300 micrograms/kg orally the GH peak came at 60 to 75 min; oral activity about 0.3% of intravenous; serum half-life 20 min; GH response matched the men's in 4 of 9 children. |
| Jaffe and colleagues, 199316 | 34-hour intravenous infusion of GHRP or saline; NIH grants listed in PubMed | 9 healthy young men | 1 microgram/kg loading bolus, then 1 microgram/kg per hour for 34 hours | Integrated GH 2908 against 1374 micrograms x min/L; IGF-I 252 to 312 micrograms/L; no change in GH pulse frequency. |
| Ghigo and colleagues, 199419 | Oral GHRP-6 before and after 4 days of twice-daily treatment; intravenous GHRH comparator | 7 normal elderly women aged 65 to 82 | Oral test dose 300 micrograms/kg before and after 4 days of twice-daily oral treatment; dose per administration not stated in the summary | GH peak 10.7 micrograms/L before and 16.8 after 4 days, against 5.1 after GHRH; IGF-I 77.1 against 84.1 micrograms/L, not significantly increased. |
| Popovic and colleagues, 20005 | Multicentre; GHRH plus GHRP-6 test compared with the insulin tolerance test (ITT) in GH-deficient cases | 125 adults with organic pituitary disease and 125 healthy people | GHRH 1 microgram/kg plus GHRP-6 1 microgram/kg intravenously, single dose | Mean GH peak 59.2 micrograms/L in controls and 4.1 in cases (ITT: 14.3 and 0.5); no side effects reported. |
| Petersenn and colleagues, 200222 | GHRP-6 alone or with GHRH on separate days, compared with the ITT | 20 patients with suspected pituitary or adrenal disease; 10 with GH deficiency | GHRP-6 1 microgram/kg, alone or with GHRH 1 microgram/kg; route not stated | GH peak 1.3 in the GH-deficient group against 25.7 micrograms/L in the others; with GHRH, 4.0 against 54.7; the only side effects observed were flush symptoms. |
| Sigalos and colleagues, 201718 | Retrospective record review; GHRP-6 with GHRP-2 and sermorelin | 14 men on testosterone therapy (mean age 33.2) of 105 prescribed the regimen | 100 mcg of each peptide subcutaneously three times daily, mean 134 days | IGF-1 rose from 159.5 to 239.0 ng/mL (p < .0001), with a non-significant trend (p = .06) toward lower IGF-1 in men on aromatase inhibitors or tamoxifen; the result is for the combination, not GHRP-6 alone. |
Deeper analysis: Bowers and colleagues, 1990
Bowers and colleagues at Tulane University gave GHRP-6 by intravenous bolus at 0.1, 0.3 and 1.0 microgram/kg to 18 normal men and compared it with placebo and with 1 microgram/kg of GHRH.1 Mean peak serum GH was 1.2 micrograms/L after placebo and 7.6, 16.5 and 68.7 micrograms/L after 0.1, 0.3 and 1.0 microgram/kg of GHRP.1 Serum prolactin and cortisol rose about 2-fold above basal levels only at the 1 microgram/kg dose.1 The authors reported no adverse clinical effects after GHRP, while a side effect of mild facial flushing lasting 1 to 3 minutes occurred in 16 of the 18 subjects who received GHRH.1 PubMed lists grants from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Center for Research Resources, and the published summary states no limitations.1
Deeper analysis: Jaffe and colleagues, 1993
Jaffe and colleagues, at the Department of Veterans Affairs Medical Center in Ann Arbor, Michigan, compared a 34-hour intravenous infusion of GHRP-6 or normal saline in nine healthy young men to test whether the pituitary stays responsive to prolonged exposure.16 Bowers, who reported the 1990 study, is among the authors, and PubMed lists NIH grants for the work.16 During the infusion the integrated GH concentration was 2908 against 1374 micrograms x min/L and plasma IGF-I rose from 252 to 312 micrograms/L, with no change in GH pulse frequency or interpulse GH concentration.16 During the infusion, baseline TSH was lower, the GH and TSH/PRL responses to GHRP and TRH were smaller, and the GH responses to GHRH boluses were augmented.16 The authors concluded that the pituitary remains sensitive to GHRP during a prolonged infusion and described the mechanisms of the GHRP effect on GH secretion as uncertain.16
Deeper analysis: Popovic and colleagues, The Lancet, 2000
Popovic and colleagues at the Institute of Endocrinology in Belgrade ran a multicentre comparison of the GHRH plus GHRP-6 test with the insulin tolerance test (ITT) in 125 adults with organic pituitary disease and 125 healthy individuals.5 Cases were defined by a GH peak of 3 micrograms/L or less after ITT, 27 controls and all cases had an ITT, and everyone received GHRH 1 microgram/kg plus GHRP-6 1 microgram/kg intravenously.5 The mean GH peak was 59.2 micrograms/L (SD 2.2) in controls and 4.1 (0.3) in cases after the combined test, against 14.3 (1.7) and 0.5 (0.06) after ITT.5 The authors reported no side effects and concluded that the test is convenient, safe and reliable for adult GH deficiency.5 PubMed tags the study as non-U.S. government research support, and the published summary names no sponsor, no author tie to a sponsor and no limitations.5
Combination regimen in men on testosterone therapy
In the Sigalos cohort, 14 of 105 men met the inclusion criteria (prescription refills within 45 days for each month's supply and baseline IGF-1 below 200 ng/mL), mean IGF-1 rose from 159.5 to 239.0 ng/mL over a mean of 134 days, testosterone and free testosterone also rose significantly from 90 days, and the three peptides were given together, so the rise is not a result for GHRP-6 alone.18 The authors state that the small and select cohort, retrospective design and short duration limit interpretation and generalizability, that anthropomorphic data were lacking and that GH levels were not assessed.18 They also state that insulin tolerance and fasting glucose levels were not evaluated, declare no conflicts of interest, and report that one author is an NIH K12 scholar.18
Doses reported in studies
| Source | Dose | Route | Length |
|---|---|---|---|
| Bowers and colleagues, 1990 | 0.1, 0.3 or 1.0 microgram/kg | Intravenous bolus | Single dose |
| Bowers, Alster and Frentz, 1992 | 100 or 300 micrograms/kg | Oral | Single dose |
| Jaffe and colleagues, 1993 | 1 microgram/kg loading bolus, then 1 microgram/kg per hour | Intravenous infusion | 34 hours |
| Ghigo and colleagues, 1994 | 300 micrograms/kg test dose; treatment dose not stated | Oral | Twice daily for 4 days |
| Frieboes and colleagues, 1995 | 4 boluses of 50 micrograms | Intravenous | Overnight |
| Frieboes and colleagues, 1999 | 300 micrograms/kg in enteric-coated capsules at 21.00 h; 30 micrograms/kg at 22.45 h | Oral; intranasal; sublingual | Overnight |
| Popovic and colleagues, 2000 | 1 microgram/kg, with GHRH 1 microgram/kg | Intravenous | Single dose |
| Petersenn and colleagues, 2002 | 1 microgram/kg, alone or with GHRH 1 microgram/kg | Not stated | Single dose on separate days |
| Cabrales and colleagues, 2013 | 100, 200 or 400 micrograms/kg | Intravenous bolus | Single dose |
| Sigalos and colleagues, 2017 | 100 mcg, with GHRP-2 and sermorelin 100 mcg each, three times daily | Subcutaneous injection | Mean 134 days |
Side effects reported
Reports from single-dose studies: Bowers and colleagues reported no adverse clinical effects after GHRP in 18 men, Popovic and colleagues reported no side effects in 250 people given GHRH plus GHRP-6, and Petersenn and colleagues reported that among 20 patients tested the only side effects observed during GHRP-6 were flush symptoms (number affected not given).1,5,22 Hormone effects were reported: prolactin and cortisol rose about 2-fold only at 1 microgram/kg in the 1990 study, and baseline TSH was lower during a 34-hour infusion.1,16 Frieboes and colleagues concluded that the effects of GHRP-6 depend upon dosage, duration and route of administration, and orally given GHRP-6 left GH, ACTH and cortisol secretion unchanged overnight, while intranasal GHRP-6 raised total-night GH significantly with a trend toward more ACTH in the first half of the night, and sublingual GHRP-6 gave a GH trend only.17
FDA's category 2 entry states that compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities.6 FDA also states that it has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.6 The Dominikowski review lists reported adverse effects across GH-axis peptides, which include GHRP-6, as prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention syndromes, musculoskeletal symptoms and injection-site reactions.7
The same review states that a characteristic effect of GHRP-6 is a consistent appetite-stimulating response, and the references it gives for that statement are a review of ghrelin and a review of growth hormone secretagogues in hypogonadal men.7 A search of PubMed on 16 November 2026 for GHRP-6 with appetite, hunger, food intake or feeding in the title or summary text, limited to humans, returned 18 records, and none of their titles names a human feeding trial of GHRP-6.
Bloodwork and markers
Sources in this part
IGF-I rose from 252 to 312 micrograms/L during a 34-hour GHRP-6 infusion in 9 men, and in 7 elderly women given oral GHRP-6 twice daily for 4 days it was 77.1 before and 84.1 micrograms/l after, not a significant increase.16,19 In 10 patients with Cushing's disease, GHRP-6 at 2 micrograms/kg intravenously raised ACTH from a basal 15.5 to a peak 45.1 pmol/l and cortisol from a basal 583.0 to a peak 1013.4 nmol/l, similar to the response to DDAVP.23
Regulatory and anti-doping status
| Authority | Entry | Detail |
|---|---|---|
| WADA Prohibited List 20263 | Section S2.2.4, growth hormone releasing factors, lists GH-releasing peptides including GHRP-6 | Section S2 is prohibited at all times, in and out of competition, and its substances are non-Specified Substances; the list came into effect on 1 January 2026. |
| FDA, category 2 of the bulk substances nominated under sections 503A or 503B6 | Growth hormone releasing peptide-6 (GHRP-6), 503B, date added 29 September 2023 | FDA states that bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies; FDA's list was current as of 22 April 2026. |
In a 2015 study, GHRP-6 was given nasally to one volunteer, was mostly excreted unchanged, and was detected in urine 23 hours after administration, while its metabolites were detectable for 12 hours only.24
What is not known
The two cited human studies that measured GHRP-6 concentrations in blood gave it orally or intravenously, so a measured subcutaneous half-life, time to peak or bioavailability is not among the figures reported here.14,2 The measured half-lives differ: 20 minutes in the 1992 study of immunoreactive GHRP, and 7.6 minutes (distribution) and 2.5 hours (elimination) in the 2013 LC-MS study, averaged over three dose levels, against the app's figure of about 20 minutes.14,2 The longest continuous exposure in the studies in the table is the 34-hour infusion, and the longest reported treatment duration is a mean of 134 days (SD 88) in a retrospective cohort that received GHRP-6 together with GHRP-2 and sermorelin.16,18 The Dominikowski review states that direct evidence for meaningful changes in body composition outcomes in humans remains limited.7 It lists the human evidence for GHRP-6 as phase I and small mechanistic human studies with no controlled efficacy trials, and states that no long term safety data are available.7
Frequently asked questions
Sources in this part
- 1Bowers et al., 1990
- 2Cabrales et al., 2013
- 3World Anti-Doping Agency, 2026
- 4Bellone et al., 1995
- 5Popovic et al., 2000
- 6US Food and Drug Administration, 2026
- 7Dominikowski et al., 2026
- 12Lawrence et al., 2002
- 14Bowers et al., 1992
- 17Frieboes et al., 1999
- 18Sigalos et al., 2017
- 21Frieboes et al., 1995
- 22Petersenn et al., 2002
What is the half-life of GHRP-6?
A 2013 intravenous study in 9 men reported a distribution half-life of 7.6 minutes and an elimination half-life of 2.5 hours for GHRP-6, averaging three dose levels.2 A 1992 study of oral GHRP-6 in 5 normal men, with intravenous data from normal men, reported a serum half-life of 20 minutes.14 The app lists about 20 minutes.
What is GHRP-6?
GHRP-6 is a hexapeptide with the sequence His-DTrp-Ala-Trp-DPhe-Lys-NH2 that raised serum growth hormone in 18 normal men in a 1990 study by Bowers and colleagues.1
Is GHRP-6 banned by WADA?
Yes: the WADA 2026 Prohibited List names GHRP-6 among the GH-releasing peptides in S2.2.4, within section S2, which is prohibited at all times, in and out of competition.3
What is the FDA status of GHRP-6?
FDA's category 2 list of bulk drug substances that may present significant safety risks names growth hormone releasing peptide-6 (GHRP-6) under 503B, with 29 September 2023 as the date added.6 FDA states that it has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.6
What did GHRP-6 do to growth hormone levels in studies?
In 18 normal men, mean peak serum GH was 1.2 micrograms/L after placebo and 7.6, 16.5 and 68.7 micrograms/L after intravenous GHRP at 0.1, 0.3 and 1.0 microgram/kg.1
What are the side effects of GHRP-6 in studies?
In single-dose studies, no adverse clinical effects were observed after GHRP in an 18-man study, and in a 250-person study the authors reported no side effects of GHRH plus GHRP-6.1,5 Among 20 patients tested, the only side effects observed during GHRP-6 were flush symptoms (number affected not given).22 Studies also reported hormone changes, FDA names safety concerns including potential effect on cortisol and increase in blood glucose, and a 2026 review lists adverse effects of GH-axis peptides such as dysglycaemia and injection-site reactions.1,6,7
Does GHRP-6 increase appetite?
In rats, intracerebroventricular injection of GHRP-6 significantly stimulated food intake.12 The 2026 Dominikowski review states that a characteristic effect of GHRP-6 is a consistent appetite-stimulating response, citing a review of ghrelin and a review of growth hormone secretagogues in hypogonadal men.7
Does GHRP-6 raise cortisol and prolactin?
By which routes has GHRP-6 been given in human studies?
Guides, tools and comparisons
References
- Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990. PMID 2108187
- Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci 2013. PMID 23099431
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. 2026. Prohibited List 2026
- Bellone J, Ghizzoni L, Aimaretti G, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol 1995. PMID 7581965
- Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 2000. PMID 11030292
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 of the bulk substances nominated under sections 503A or 503B). 2026. FDA page
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
- Micic D, Macut D, Sumarac-Dumanovic M, et al. Ghrelin-induced GH secretion in normal subjects is partially resistant to homologous desensitization by GH-releasing peptide-6. Eur J Endocrinol 2002. PMID 12457451
- Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993. PMID 8473389
- Popovic V, Damjanovic S, Micic D, et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995. PMID 7883854
- Pombo M, Barreiro J, Peñalva A, et al. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995. PMID 7593423
- Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002. PMID 11751604
- Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol 2024. PMID 38873418
- Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 1992. PMID 1730807
- Nelson AH, Walker RF, Codd EE, Barone FC. Intranasal activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in conscious dogs. Life Sci 1991. PMID 2046459
- Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993. PMID 7903313
- Frieboes RM, Murck H, Antonijevic IA, Steiger A. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol 1999. PMID 10336729
- Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health 2017. PMC5675260
- Ghigo E, Arvat E, Rizzi G, et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol 1994. PMID 7952160
- Walker RF, Codd EE, Barone FC, et al. Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeys. Life Sci 1990. PMID 2117689
- Frieboes RM, Murck H, Maier P, et al. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995. PMID 7617137
- Petersenn S, Jung R, Beil FU. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test. Eur J Endocrinol 2002. PMID 11980622
- Oliveira JH, Vieira JG, Abucham J, Lengyel AM. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP. J Endocrinol Invest 2003. PMID 12809173
- Semenistaya E, Zvereva I, Thomas A, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal 2015. PMID 25869809